vs
CATALYST PHARMACEUTICALS, INC.（CPRX）与OCTAVE SPECIALTY GROUP INC（OSG）财务数据对比。点击上方公司名可切换其他公司
CATALYST PHARMACEUTICALS, INC.的季度营收约是OCTAVE SPECIALTY GROUP INC的1.5倍（$152.6M vs $104.2M），CATALYST PHARMACEUTICALS, INC.净利率更高（34.5% vs -6.6%，领先41.1%），OCTAVE SPECIALTY GROUP INC同比增速更快（66.0% vs 7.6%），过去两年OCTAVE SPECIALTY GROUP INC的营收复合增速更高（42.9% vs 24.5%）
Catalyst Pharmaceuticals是一家总部位于美国佛罗里达州科勒尔盖布尔斯的生物制药企业，专注于罕见病药物研发。核心产品包括用于治疗兰伯特-伊顿肌无力综合征（LEMS）的氨吡啶磷酸盐，商品名为Firdapse。该药物2018年11月获FDA批准，除原有成人适应症外，还可用于6岁及以上的LEMS儿童患者。
奥克塔夫专业集团是一家专业保险控股企业，主营定制化财产与意外伤害保险产品，核心业务聚焦超额剩余保险领域，为北美地区的商业及个人客户提供定制化风险保障解决方案。
CPRX vs OSG — 直观对比
营收规模更大
CPRX
是对方的1.5倍
$104.2M
营收增速更快
OSG
高出58.4%
7.6%
净利率更高
CPRX
高出41.1%
-6.6%
两年增速更快
OSG
近两年复合增速
24.5%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $152.6M | $104.2M |
| 净利润 | $52.7M | $-6.9M |
| 毛利率 | 82.9% | — |
| 营业利润率 | 40.5% | — |
| 净利率 | 34.5% | -6.6% |
| 营收同比 | 7.6% | 66.0% |
| 净利润同比 | -5.8% | — |
| 每股收益（稀释后） | $0.40 | $-0.13 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CPRXOSG
| Q1 26 | — | $104.2M | ||
| Q4 25 | $152.6M | $66.9M | ||
| Q3 25 | $148.4M | $66.6M | ||
| Q2 25 | $146.6M | $55.0M | ||
| Q1 25 | $141.4M | $62.8M | ||
| Q4 24 | $141.8M | $65.2M | ||
| Q3 24 | $128.7M | $70.0M | ||
| Q2 24 | $122.7M | $51.0M |
净利润CPRXOSG
| Q1 26 | — | $-6.9M | ||
| Q4 25 | $52.7M | $-29.7M | ||
| Q3 25 | $52.8M | $-112.6M | ||
| Q2 25 | $52.1M | $-72.7M | ||
| Q1 25 | $56.7M | $-44.7M | ||
| Q4 24 | $55.9M | $-20.9M | ||
| Q3 24 | $43.9M | $-27.5M | ||
| Q2 24 | $40.8M | $-750.0K |
毛利率CPRXOSG
| Q1 26 | — | — | ||
| Q4 25 | 82.9% | — | ||
| Q3 25 | 84.7% | — | ||
| Q2 25 | 85.9% | — | ||
| Q1 25 | 87.3% | — | ||
| Q4 24 | 84.7% | — | ||
| Q3 24 | 85.0% | — | ||
| Q2 24 | 87.4% | — |
营业利润率CPRXOSG
| Q1 26 | — | — | ||
| Q4 25 | 40.5% | -76.7% | ||
| Q3 25 | 44.7% | -48.2% | ||
| Q2 25 | 45.2% | -41.8% | ||
| Q1 25 | 44.8% | -24.1% | ||
| Q4 24 | 44.3% | -55.5% | ||
| Q3 24 | 39.6% | -29.7% | ||
| Q2 24 | 44.2% | -28.9% |
净利率CPRXOSG
| Q1 26 | — | -6.6% | ||
| Q4 25 | 34.5% | -73.8% | ||
| Q3 25 | 35.6% | -169.1% | ||
| Q2 25 | 35.6% | -132.3% | ||
| Q1 25 | 40.1% | -71.3% | ||
| Q4 24 | 39.4% | -55.1% | ||
| Q3 24 | 34.1% | -39.3% | ||
| Q2 24 | 33.2% | -1.5% |
每股收益（稀释后）CPRXOSG
| Q1 26 | — | $-0.13 | ||
| Q4 25 | $0.40 | $-0.82 | ||
| Q3 25 | $0.42 | $-2.35 | ||
| Q2 25 | $0.41 | $-1.54 | ||
| Q1 25 | $0.45 | $-1.22 | ||
| Q4 24 | $0.44 | $-11.75 | ||
| Q3 24 | $0.35 | $-0.63 | ||
| Q2 24 | $0.33 | $-0.02 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $709.2M | — |
| 总债务越低越好 | — | $117.1M |
| 股东权益账面价值 | $954.3M | $833.6M |
| 总资产 | $1.1B | $2.3B |
| 负债/权益比越低杠杆越低 | — | 0.14× |
8季度趋势，按日历期对齐
现金及短期投资CPRXOSG
| Q1 26 | — | — | ||
| Q4 25 | $709.2M | $146.4M | ||
| Q3 25 | $689.9M | $27.5M | ||
| Q2 25 | $652.8M | $22.5M | ||
| Q1 25 | $580.7M | $34.1M | ||
| Q4 24 | $517.6M | $157.2M | ||
| Q3 24 | $442.3M | $40.8M | ||
| Q2 24 | $375.7M | $14.6M |
总债务CPRXOSG
| Q1 26 | — | $117.1M | ||
| Q4 25 | — | $117.6M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $0 | ||
| Q3 24 | — | $518.0M | ||
| Q2 24 | — | $515.0M |
股东权益CPRXOSG
| Q1 26 | — | $833.6M | ||
| Q4 25 | $954.3M | $715.8M | ||
| Q3 25 | $920.2M | $843.4M | ||
| Q2 25 | $856.0M | $859.8M | ||
| Q1 25 | $794.3M | $852.2M | ||
| Q4 24 | $727.6M | $798.4M | ||
| Q3 24 | $660.9M | $1.5B | ||
| Q2 24 | $608.7M | $1.4B |
总资产CPRXOSG
| Q1 26 | — | $2.3B | ||
| Q4 25 | $1.1B | $2.2B | ||
| Q3 25 | $1.1B | $2.1B | ||
| Q2 25 | $971.9M | $8.5B | ||
| Q1 25 | $908.9M | $8.3B | ||
| Q4 24 | $851.4M | $8.1B | ||
| Q3 24 | $772.0M | $9.3B | ||
| Q2 24 | $706.4M | $8.2B |
负债/权益比CPRXOSG
| Q1 26 | — | 0.14× | ||
| Q4 25 | — | 0.16× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.00× | ||
| Q3 24 | — | 0.35× | ||
| Q2 24 | — | 0.38× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $44.9M | — |
| 自由现金流经营现金流 - 资本支出 | $44.9M | — |
| 自由现金流率自由现金流/营收 | 29.4% | — |
| 资本支出强度资本支出/营收 | 0.0% | — |
| 现金转化率经营现金流/净利润 | 0.85× | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流CPRXOSG
| Q1 26 | — | — | ||
| Q4 25 | $44.9M | $-52.3M | ||
| Q3 25 | $32.4M | $-41.2M | ||
| Q2 25 | $71.3M | $2.1M | ||
| Q1 25 | $60.0M | $-12.6M | ||
| Q4 24 | $70.9M | $762.0K | ||
| Q3 24 | $72.9M | $48.9M | ||
| Q2 24 | $64.1M | $20.4M |
自由现金流CPRXOSG
| Q1 26 | — | — | ||
| Q4 25 | $44.9M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $71.3M | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $70.8M | — | ||
| Q3 24 | $72.6M | — | ||
| Q2 24 | $64.1M | — |
自由现金流率CPRXOSG
| Q1 26 | — | — | ||
| Q4 25 | 29.4% | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 48.6% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 49.9% | — | ||
| Q3 24 | 56.4% | — | ||
| Q2 24 | 52.3% | — |
资本支出强度CPRXOSG
| Q1 26 | — | — | ||
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.0% | — | ||
| Q4 24 | 0.1% | — | ||
| Q3 24 | 0.2% | — | ||
| Q2 24 | 0.0% | — |
现金转化率CPRXOSG
| Q1 26 | — | — | ||
| Q4 25 | 0.85× | — | ||
| Q3 25 | 0.61× | — | ||
| Q2 25 | 1.37× | — | ||
| Q1 25 | 1.06× | — | ||
| Q4 24 | 1.27× | — | ||
| Q3 24 | 1.66× | — | ||
| Q2 24 | 1.57× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CPRX
| Firdapse | $97.6M | 64% |
| Agamree | $35.3M | 23% |
| Fycompa | $19.6M | 13% |
OSG
| Commissions | $68.2M | 65% |
| Other | $20.6M | 20% |
| Servicing and other fees | $9.4M | 9% |
| Program fees | $3.6M | 3% |
| Investment income | $2.4M | 2% |
